TECH Bio-techne (TECH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000842023
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
294
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $9.6M priced
What the filings say about TECH
Insiders, 180 days
-$320.4K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-04-08
Bio-techne insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIO-TECHNE Corp insiders sold a net $320.4K of stock across 87 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 17, 2026.
- The trade is 3318.0% of the 200 shares held after it.
- No other insider sold within 30 days.
- 294 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herr Amy E. sold about $320.4K of TECH on May 8, 2026; 294 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 9, 2025.
- The trade is 988.0% of the 200 shares held after it.
- No other insider sold within 30 days.
- 294 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herr Amy E. sold about $116.8K of TECH on Feb 17, 2026; 294 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 7, 2024.
- The trade is 38.2% of the 44,559 shares held after it.
- 1 other insider sold within 30 days.
- 294 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nusse Roeland sold about $960.4K of TECH on Aug 25, 2025, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 294 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Aug 8, 2024.
- The trade is 38.0% of the 44,863 shares held after it.
- 1 other insider sold within 30 days.
- 294 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BAUMGARTNER ROBERT V sold about $957.8K of TECH on Aug 25, 2025, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 294 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 14, 2025.
- The trade is 64.8% of the 1,976 shares held after it.
- No other insider sold within 30 days.
- 294 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herr Amy E. sold about $63.7K of TECH on Jun 9, 2025; 294 funds added in the latest 13F quarter.87 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$320.4K over 180 days
below 51% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
294 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
-0.4% year over year
below 57% of Pharma & Biotech
Margin
15.0% net margin
more than 85% of Pharma & Biotech
Buybacks
$41.7M repurchased, FY to 2026-06-30
more than 54% of Pharma & Biotech
Short interest
4.8% of the float short (float per yahoo 2026-10-27) · 2.9 days to cover · settled 2026-10-15
more than 50% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TECH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+10.4%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TECH: institutional holders (13F)
13F holdings, latest reported quarter
14,025,816 sh
$990.9M
12,794,784 sh
$904.0M
10,218,558 sh
$721.9M
7,343,324 sh
$518.8M
6,825,000 sh
$482.2M
Congress trades in TECH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-04-08 · disclosed 28 days later
$1,001 - $15,000
Sold 2026-03-26 · disclosed 11 days later
$1,001 - $15,000
Sold 2026-02-24 · disclosed 14 days later
$1,001 - $15,000
Sold 2026-01-28 · disclosed 5 days later
$1,001 - $15,000
Bought 2025-12-05 · disclosed 31 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TECH planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TECH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity SAI Merger Arbitrage Fund
$27.1M position · as of 2026-07-31
4.2%
CRM SMALL/MID CAP VALUE FUND
$7.2M position · as of 2026-07-31
4.0%
DF DENT MIDCAP GROWTH FUND
$9.1M position · as of 2026-06-30
4.0%
Mairs & Power Small Cap Fund
$10.6M position · as of 2026-06-30
3.9%
Invesco Biotechnology & Genome ETF
$10.5M position · as of 2026-07-31
3.7%
First Trust NYSE Arca Biotechnology Index Fund
$96.5M position · as of 2026-06-30
3.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $320.4K sold by insiders over 180 days, 294 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
TECH financials
Revenue growth
-0.4%
XBRL, annual
Net margin
15.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TECH
| FY Jun 2026 | $1.2B |
| FY Jun 2025 | $1.2B |
| FY Jun 2024 | $1.2B |
| FY Jun 2023 | $1.1B |
| FY Jun 2022 | $1.1B |
| Jun 2026 | $321.2M |
| Mar 2026 | $311.4M |
| Dec 2025 | $295.9M |
| Sep 2025 | $286.6M |
| Jun 2025 | $317.0M |
| Mar 2025 | $316.2M |
| Dec 2024 | $297.0M |
| Sep 2024 | $289.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TECH
| FY Jun 2026 | +15.0% |
| FY Jun 2025 | +6.0% |
| FY Jun 2024 | +14.5% |
| FY Jun 2023 | +25.1% |
| FY Jun 2022 | +24.6% |
| Jun 2026 | +17.0% |
| Mar 2026 | +16.4% |
| Dec 2025 | +12.8% |
| Sep 2025 | +13.3% |
| Jun 2025 | -5.6% |
| Mar 2025 | +7.1% |
| Dec 2024 | +11.7% |
| Sep 2024 | +11.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$263.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TECH
| FY Jun 2026 | $263.2M |
| FY Jun 2025 | $256.6M |
| FY Jun 2024 | $236.1M |
| FY Jun 2023 | $216.1M |
| FY Jun 2022 | $280.4M |
| Jun 2026 | $86.9M |
| Mar 2026 | $77.6M |
| Dec 2025 | $76.5M |
| Sep 2025 | $22.2M |
| Jun 2025 | $93.3M |
| Mar 2025 | $31.0M |
| Dec 2024 | $77.5M |
| Sep 2024 | $54.7M |
At each fiscal year end
Single quarter
Debt to equity
0.10x
long-term 2026-06-30 plus current 2022-06-30 (48 months older than the period end); equity 2026-06-30
Debt to equity TECH
| FY Jun 2026 | 0.10x |
| FY Jun 2025 | 0.19x |
| FY Jun 2024 | 0.16x |
| FY Jun 2023 | 0.18x |
| FY Jun 2022 | 0.15x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.10x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.15x |
| Sep 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.37x
TTM operating cash flow over long-term 2026-06-30 plus current 2022-06-30 (48 months older than the period end)
Cash flow to debt TECH
| FY Jun 2026 | 1.37x |
| FY Jun 2025 | 0.80x |
| FY Jun 2024 | 0.90x |
| FY Jun 2023 | 0.70x |
| FY Jun 2022 | 1.27x |
| Jun 2026 | 1.37x |
| Mar 2026 | 1.39x |
| Dec 2025 | 0.91x |
| Sep 2025 | 0.80x |
| Jun 2025 | 0.80x |
| Mar 2025 | 0.77x |
| Dec 2024 | 0.98x |
| Sep 2024 | 0.97x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+9.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TECH
| FY Jun 2026 | +9.0% |
| FY Jun 2025 | +3.7% |
| FY Jun 2024 | +8.3% |
| FY Jun 2023 | +15.6% |
| FY Jun 2022 | +16.7% |
| Jun 2026 | +9.0% |
| Mar 2026 | +5.3% |
| Dec 2025 | +4.0% |
| Sep 2025 | +3.8% |
| Jun 2025 | +3.7% |
| Mar 2025 | +6.5% |
| Dec 2024 | +7.8% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TECH
| FY Jun 2026 | +7.1% |
| FY Jun 2025 | +2.8% |
| FY Jun 2024 | +6.3% |
| FY Jun 2023 | +11.6% |
| FY Jun 2022 | +11.9% |
| Jun 2026 | +7.1% |
| Mar 2026 | +4.2% |
| Dec 2025 | +3.1% |
| Sep 2025 | +3.0% |
| Jun 2025 | +2.8% |
| Mar 2025 | +4.9% |
| Dec 2024 | +5.9% |
| Sep 2024 | +5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+9.5%
operating income after a 24.4% effective tax rate, over long-term 2026-06-30 plus current 2022-06-30 (48 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital TECH
| FY Jun 2026 | +9.5% |
| FY Jun 2025 | +3.5% |
| FY Jun 2024 | +8.6% |
| FY Jun 2023 | +12.5% |
| FY Jun 2022 | +15.2% |
| Jun 2026 | +9.5% |
| Mar 2026 | +5.5% |
| Dec 2025 | +3.9% |
| Sep 2025 | +3.7% |
| Jun 2025 | +3.5% |
| Mar 2025 | +6.3% |
| Dec 2024 | +7.8% |
| Sep 2024 | +7.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TECH
| FY Jun 2026 | +10.5% |
| FY Jun 2025 | +4.2% |
| FY Jun 2024 | +8.2% |
| FY Jun 2023 | +12.9% |
| FY Jun 2022 | +14.0% |
| Jun 2026 | +10.5% |
| Mar 2026 | +6.3% |
| Dec 2025 | +4.8% |
| Sep 2025 | +4.4% |
| Jun 2025 | +4.2% |
| Mar 2025 | +6.8% |
| Dec 2024 | +7.8% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
63.13x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing TECH
| FY Jun 2026 | 61.43x |
| FY Jun 2025 | 111.85x |
| FY Jun 2024 | 68.24x |
| FY Jun 2023 | 46.65x |
| FY Jun 2022 | 29.58x |
| Jun 2026 | 61.43x |
| Mar 2026 | 75.74x |
| Dec 2025 | 115.31x |
| Sep 2025 | 113.53x |
| Jun 2025 | 111.85x |
| Mar 2025 | 70.64x |
| Dec 2024 | 72.03x |
| Sep 2024 | 84.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$11.3B
market value at close 2026-10-27 on 2026-08-17 shares, plus long-term 2026-06-30 plus current 2022-06-30 (48 months older than the period end), minus cash 2026-06-30
Enterprise value TECH
| FY Jun 2026 | $11.0B |
| FY Jun 2025 | $8.3B |
| FY Jun 2024 | $11.5B |
| FY Jun 2023 | $13.0B |
| FY Jun 2022 | $3.5B |
| Jun 2026 | $11.0B |
| Mar 2026 | $8.2B |
| Dec 2025 | $9.3B |
| Sep 2025 | $8.8B |
| Jun 2025 | $8.3B |
| Mar 2025 | $9.5B |
| Dec 2024 | $11.6B |
| Sep 2024 | $12.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield TECH
| FY Jun 2026 | +2.4% |
| FY Jun 2025 | +3.2% |
| FY Jun 2024 | +2.1% |
| FY Jun 2023 | +1.7% |
| FY Jun 2022 | +8.2% |
| Jun 2026 | +2.4% |
| Mar 2026 | +3.3% |
| Dec 2025 | +2.4% |
| Sep 2025 | +2.6% |
| Jun 2025 | +3.2% |
| Mar 2025 | +2.4% |
| Dec 2024 | +2.2% |
| Sep 2024 | +1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.42x
P/E over trailing EPS growth of 150%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing TECH
| FY Jun 2026 | 0.41x |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | 0.12x |
| Jun 2026 | 0.41x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.2B | $1.1B |
| Gross profit | $799.1M | $790.3M | $769.7M | $769.8M |
| Operating income | $251.9M | $102.3M | $206.7M | $298.9M |
| Net income | $181.9M | $73.4M | $168.1M | $285.3M |
| EPS (diluted) | 1.16 | 0.46 | 1.05 | 1.76 |
| Operating cash flow | $292.1M | $287.6M | $299.0M | $254.4M |
| Cash | $264.7M | $162.2M | $151.8M | $180.6M |
| Long-term debt | $200.0M | $346.0M | $319.0M | $350.0M |
| Buybacks | $41.7M | $275.7M | $80.0M | $19.6M |
| Dividends paid | $49.9M | $50.4M | $50.4M | $50.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
TECH Stock Sonar score 6/7 axes
Find similar shapesCompareTECH ranks highest on profitability (74th percentile) and financial health (74th), and lowest on insider conviction (23rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TECH filings, in plain words
Are Bio-techne insiders buying or selling TECH?
In the 180 days to 2026-10-28, Bio-techne insiders were net sellers, a net $320.4K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded TECH?
Yes. In the year to 2026-10-28, 1 House member disclosed buying TECH and 1 House member disclosed selling it; the latest on record is a sale by April McClain Delaney dated 2026-04-08.
Read the full summary
In the 180 days to 2026-10-28, Bio-techne insiders were net sellers of TECH, a net $320.4K across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-28, 1 member of Congress disclosed buying TECH and 1 member disclosed selling it; the latest on record is a sale by April McClain Delaney dated 2026-04-08. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
